Keywords: Spectrum Pharma, Allos Thera, Apaziquone, Bladder cancer, Ph III, M&A, Folotyn
Spectrum plunges on negative trial results; makes bid for Allos
Article | 10 April 2012
US biotech firm Spectrum Pharmaceuticals (Nasdaq: SPPI) saw its shares plunge as much as 14%, before closing down 7.9% at $11.25 last Thursday, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
